Read by QxMD icon Read

Gynecologic Oncology

Mark H Stoler, Thomas C Wright, Valentin Parvu, Laurence Vaughan, Karen Yanson, Karen Eckert, Tobi Karchmer, Salma Kodsi, Charles K Cooper
OBJECTIVES: The baseline phase of the Onclarity trial was conducted to determine the screening performance of the Onclarity human papillomavirus (HPV) assay for detecting cervical cancer and precancer (≥CIN2) during triage of women ≥21 years with ASC-US cytology, as an adjunct test in women ≥30 years with normal cytology and for primary screening (HPV alone) in women ≥25 years. METHODS: 33,858 women ≥21 years were enrolled during routine clinic visits...
April 19, 2018: Gynecologic Oncology
Sarah E Ferguson, Tony Panzarella, Susie Lau, Lilian T Gien, Vanessa Samouëlian, Christopher Giede, Helen Steed, Tien Le, Ben Renkosinski, Marcus Q Bernardini
OBJECTIVE: To evaluate patient-reported outcomes (PROs) between women treated by laparoscopic, robotic and open approaches for endometrial cancer. METHODS: Prospective cohort study comparing PRO at baseline, short- (1 and 3 weeks) and long-term (12 and 24 weeks) follow-up postoperatively. Quality of life (QOL) measures were the Functional Assessment of Cancer Therapy (FACT-G), EuroQol Five Dimensions (EQ-5D), and Brief Pain Inventory (BPI). Sexual health measures were the Female Sexual Function Index (FSFI) and the Sexual Adjustment and Body Image Scale for Gynecologic Cancer (SABIS-G)...
April 19, 2018: Gynecologic Oncology
Mariam El-Zein, Sheila Bouten, Karolina Louvanto, Lucy Gilbert, Walter Gotlieb, Robert Hemmings, Marcel A Behr, Eduardo L Franco, Victoria Liang, Claudia Martins, Silvy Duarte, Natalia Sarban, Patricia Geddes, Ana Massa, Kathrin Samios, Siham Aboufadl, Sophie Verdon, Cynthia Pereria, Isabelle Lacroix
OBJECTIVE: We compared the self-sampling performance of the newly designed HerSwab™ device with a physician-collected cervical sample and another self-sample using the cobas® PCR Female swab for the detection of cervical intraepithelial neoplasia (CIN) and cancer. METHODS: Women referred for colposcopy at McGill University affiliated hospital clinics collected two consecutive self-samples, one with HerSwab™ and one with cobas® swab, after receiving instructions...
April 17, 2018: Gynecologic Oncology
Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Enomoto, Daisuke Aoki, Toru Sugiyama
OBJECTIVE: This multicenter phase II Japanese Gynecologic Oncology Group study (JGOG1067) was designed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer. METHODS: Patients with stage IB-IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study. The patients postoperatively received irinotecan (CPT-11; 60mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80mg/m2 intravenously on day 1)...
April 13, 2018: Gynecologic Oncology
Brittany F Lees, Taylor P Stewart, Joanne K Rash, Shirley R Baron, Stacy Tessler Lindau, David M Kushner
More than 30% of women have a history of abuse. Women with cancer may be at substantially increased risk for abuse, but this issue is rarely discussed in the course of oncology care. Women with a history of abuse who present for cancer care commonly have a high prevalence of co-morbid illness. Sexual dysfunction, a highly prevalent but under-recognized condition among women of all ages, is also more common among both women with a history of abuse and women with cancer. Although common after cancer, sexual dysfunction, like abuse, can be stigmatizing and often goes undiagnosed and untreated...
April 13, 2018: Gynecologic Oncology
Jennifer E Bergstrom, Marla E Scott, Yewande Alimi, Ting-Tai Yen, Deborah Hobson, Karime K Machado, Edward J Tanner, Amanda N Fader, Sarah M Temkin, Stephanie Wethington, Kimberly Levinson, Sam Sokolinsky, Brandyn Lau, Rebecca L Stone
OBJECTIVES: Enhanced Recovery After Surgery (ERAS) programs are mechanisms for achieving value-based improvements in surgery. This report provides a detailed analysis of the impact of an ERAS program on patient outcomes as well as quality and safety measures during implementation on a gynecologic oncology service at a major academic medical center. METHODS: A retrospective review of gynecologic oncology patients undergoing elective laparotomy during the implementation phase of an ERAS program (January 2016 through December 2016) was performed...
April 13, 2018: Gynecologic Oncology
David B Chapel, S Diane Yamada, Matthew Cowan, Ricardo R Lastra
OBJECTIVE: Universal screening of endometrial cancer (EC) for Lynch syndrome (LS) has been increasingly implemented in the past five to ten years. Most pathologists initiate screening with immunohistochemistry (IHC) for mismatch repair proteins (MMRPs), using either pre-surgical samplings (endometrial biopsy or curettage, EMB/C) or hysterectomy specimens. We report a systematic assessment of the equivalence of IHC for LS screening on EMB/C versus hysterectomy specimens. METHODS: We identified 99 patients diagnosed with endometrioid EC and performed IHC for MMRPs MLH1, MSH2, MSH6, and PMS2 on their diagnostic EMB/C and paired hysterectomy specimen...
April 13, 2018: Gynecologic Oncology
Fang Jiang, Xi-Run Wan, Tao Xu, Feng-Zhi Feng, Tong Ren, Jun-Jun Yang, Jun Zhao, Tao Yang, Yang Xiang
BACKGROUND: To re-evaluate the efficacy of the prognostic factors currently employed in the treatment of malignant gestational trophoblastic neoplasia. METHODS: Clinical data from the Gestational Trophoblastic Disease (GTD) Center at Peking Union Medical Hospital (PUMCH) collected between January 2002 and December 2013 were retrospectively analyzed. Univariate and multivariate analyses of prognostic factors were performed using the Cox proportional hazards model...
April 10, 2018: Gynecologic Oncology
Denise Uyar, Jamie Neary, Amy Monroe, Melodee Nugent, Pippa Simpson, Jennifer L Geurts
OBJECTIVE: The National Comprehensive Cancer Network recommends all women with ovarian cancer be offered genetic testing. Despite a decade of endorsement, many oncology practitioners have yet to make this a part of routine practice. Referral to genetic counseling and completion of genetic testing among patients at substantial risk of germline mutations are significantly lacking, adversely affecting patient care and squandering an opportunity to maximize cancer prevention efforts. This project determined the impact and feasibility of implementing a basic model for universal referral to genetic counseling and completion of genetic testing in women with a diagnosis of ovarian cancer in an academic gynecology oncology practice with access to electronic health records (EHRs)...
April 10, 2018: Gynecologic Oncology
Joyce Liu, Shibani Nicum, Peter Reichardt, Kenneth Croitoru, Beate Illek, Manuela Schmidinger, Catherine Rogers, Christin Whalen, Gordon C Jayson
Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PARP) inhibitors, or with and following cytotoxic chemotherapy. If VEGFR-TKIs are licensed for use in ovarian cancer, patients will require prompt and effective management of adverse events, including diarrhea, to optimize compliance and benefit...
April 4, 2018: Gynecologic Oncology
Shannon D Armbruster, Charlotte C Sun, Shannon N Westin, Diane C Bodurka, Lois Ramondetta, Larissa A Meyer, Pamela T Soliman
OBJECTIVE: Pelvic exenteration (PE) is a surgical procedure associated with significant morbidity offered to select women with locally advanced or recurrent gynecologic cancers. This ongoing study examines an array of patient-reported outcomes and satisfaction with PE. METHODS: Since February 2009, prospectively enrolled participants completed questionnaires evaluating body image (BIS), depression (CESD), social support (DUFSS), symptoms (MDASI), sexual function (SAQ), functional status (SF-12), quality of life (The Stoma-QOL), satisfaction with decision (SWD) and an investigator-designed survey at baseline, 6, and 12months after PE...
April 2, 2018: Gynecologic Oncology
Chuenkamon Charakorn, Kunlawat Thadanipon, Sawarat Chaijindaratana, Sasivimol Rattanasiri, Pawin Numthavaj, Ammarin Thakkinstian
OBJECTIVE: The aim of this systematic review and meta-analysis was to pool association effects of serum squamous cell carcinoma antigen (SCC-Ag) on recurrence and mortality in mainly squamous cell cervical cancer patients. METHODS: MEDLINE and Scopus databases were searched up to June 29, 2016. Studies assessing effects of SCC-Ag on recurrence and death in cervical cancer patients were included. Data extraction was independently performed by two reviewers. A meta-analysis was applied for pooling the effects (i...
March 29, 2018: Gynecologic Oncology
Cynthia S Bonhof, Floortje Mols, M Caroline Vos, Johanna M A Pijnenborg, Dorry Boll, Gerard Vreugdenhil, Nicole P M Ezendam, Lonneke V van de Poll-Franse
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) presents itself as sensory peripheral neuropathy (SPN) or motor peripheral neuropathy (MPN). Our aim was to examine the course of SPN and MPN, and their impact on health-related quality of life (HRQoL) among ovarian cancer patients. METHODS: All newly diagnosed ovarian cancer patients from twelve hospitals in the South of the Netherlands were eligible for participation. Patients (N=174) completed questions on CIPN (EORTC QLQ-OV28) and HRQoL (EORTC QLQ-C30) after initial treatment and at 6, 12, and 24months (response rates were 70%, 71%, 58%, and 43% respectively)...
March 28, 2018: Gynecologic Oncology
Hongrong Wu, Jian Zhang
BACKGROUND: Transcription factor activator protein-2β (TFAP-2β) was previously reported to constituted promoter activity in endometrial carcinoma (EC). We evaluated the role of TFAP2B in ECs using publicly available data from The Cancer Genome Atlas (TCGA). METHODS: The relationship between clinical pathologic features and TFAP2B were analyzed with the Wilcoxon signed-rank test and logistic regression. Clinicopathologic characteristics associated with overall survival in TCGA patients using Cox regression and the Kaplan-Meier method...
March 28, 2018: Gynecologic Oncology
Jennifer Cunningham-Erves, Laura Forbes, Nataliya Ivankova, Tilicia Mayo-Gamble, Kendria Kelly-Taylor, Jason Deakings
OBJECTIVE: The cervical cancer disparity continues to exist and has widened between Black and non-Hispanic White women. Human Papillomavirus (HPV) vaccines could potentially reduce this disparity, yet remain underused among Black female adolescents. We investigated psychosocial and cultural factors associated with Black mothers' intentions to vaccinate their daughters against HPV, and explored views toward a HPV vaccine mandate. METHODS: In this quantitative dominant, mixed methods study, cross sectional surveys (n=237) and follow-up semi-structured interviews (n=9) were conducted with Black mothers of daughters...
March 24, 2018: Gynecologic Oncology
Elisabet Mattsson, Kim Einhorn, Lisa Ljungman, Inger Sundström-Poromaa, Karin Stålberg, Anna Wikman
OBJECTIVE: To investigate the prevalence and predictors of cancer-related distress in younger women treated for gynaecological cancer, and to explore women's needs and experiences of psychosocial support following end-of-treatment. METHODS: Data were collected from 337 gynaecological cancer survivors, 19-39years at diagnosis, using a study-specific questionnaire and the Swedish Quality Register of Gynaecologic Cancer. Predictors of distress were investigated with multivariable logistic regression analysis...
March 24, 2018: Gynecologic Oncology
Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Makio Shozu
No abstract text is available yet for this article.
March 21, 2018: Gynecologic Oncology
Jing Long, Jun-You Zhu, Yong-Bin Liu, Kun Fu, Yan Tian, Pei-Yao Li, Wen-Qing Yang, Si-Yu Yang, Ji-Ye Yin, Gang Yin, Yu Zhang
OBJECTIVE: To investigate the role of HELQ in chemo-resistance of epithelial ovarian carcinoma (EOC), which is a critical factor of patients' prognosis. METHODS: Immunohistochemistry, survival analysis of our 87 EOC patients and bioinformatics analysis of The Cancer Genome Atlas (TCGA) datasets (Nature, 2011) disclosed the clinical importance of HELQ expression. Quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western Blot analyses of EOC tissue were used to confirm it...
March 20, 2018: Gynecologic Oncology
Long Chen, Shaohong Luan, Baoguo Xia, Yansheng Liu, Yuan Gao, Hongyan Yu, Qingling Mu, Ping Zhang, Weina Zhang, Shengmiao Zhang, Guopeng Wei, Min Yang, Ke Li
OBJECTIVE: Human papillomavirus (HPV) infection is the primary cause of cervical cancer. HPV-mediated immune alterations are known to play crucial roles in determining viral persistence and host cell transformation. We sought to thoroughly understand HPV-directed immune alterations in cervical cancer by exploring publically available datasets. METHODS: 130 HPV positive and 7 HPV negative cervical cancer cases from The Cancer Genome Atlas were compared for differences in gene expression levels and functional enrichment...
March 20, 2018: Gynecologic Oncology
Jisup Kim, Sinae Kim, Hye Sun Lee, Wookyeom Yang, Hanbyoul Cho, Doo Byung Chay, Seong Jin Cho, Soonwon Hong, Jae-Hoon Kim
OBJECTIVE: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. METHODS: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS)...
March 20, 2018: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"